Lee Connor, MD
Infectious Disease · Dalton, GANPI 1710307129
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,450 of the $14,458 with a category attached, or 65.4%. AbbVie accounts for 76.1% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2024 at $6,157 and has fallen 64.9% since, to $2,160 in 2025.
Across 232 payments — averaging $62.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Insmed, Inc.$712
- Boehringer Ingelheim$348
- Gilead$347
- UCB, Inc.$318
- Amgen$268
- plus $1K from 27 others
What the payments were for
- Speaking & faculty fees$9,45065%
- Travel & lodging$710%
- Food & beverage$4,70933%
- Education$1661%
- Entertainment$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 77 | $11,000 |
| Insmed, Inc. | 27 | $712 |
| Boehringer Ingelheim | 15 | $348 |
| Gilead | 17 | $347 |
| UCB, Inc. | 20 | $318 |
| Amgen | 12 | $268 |
| Melinta Therapeutics, LLC | 10 | $224 |
| La Jolla Pharmaceutical Company | 8 | $198 |
| United Therapeutics Corporation | 6 | $157 |
| Mallinckrodt Hospital Products Inc. | 4 | $134 |
| Actelion Pharmaceuticals US, Inc. | 3 | $71 |
| Ferring Pharmaceuticals Inc. | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 4 | $70 |
| Qiagen, LLC | 1 | $62 |
| Grifols USA, LLC | 3 | $53 |
| Shionogi Inc | 2 | $45 |
| Sanofi | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Merck | 2 | $32 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $30 |
| CSL Behring | 1 | $22 |
| Vapotherm Inc | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
| Organogenesis Inc. | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Verona Pharma, Inc. | 1 | $18 |
| GSK | 1 | $18 |
| Biomerieux Inc | 1 | $17 |
| Heartflow, Inc. | 1 | $16 |
| Viiv Healthcare Company | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $15 |
| Mayne Pharma Commercial LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,458 in reported general payments places this provider in the 85th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $48,022 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $42,779 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 24 | $25,804 |
| Daptomycin | 39 | $25,566 |
| Fosfomycin Tromethamine | 29 | $7,759 |
| ErtapenemErtapenem Sodium | 19 | $6,418 |
| Methenamine Hippurate | 81 | $5,107 |
| Cefepime Hcl | 19 | $4,559 |
| Cefpodoxime Proxetil | 24 | $3,361 |
| CeftriaxoneCeftriaxone Sodium | 44 | $1,769 |
| Doxycycline Hyclate | 48 | $867 |
| Fluconazole | 19 | $817 |
| Minocycline Hcl | 22 | $680 |
| Amoxicillin | 24 | $405 |
| Azithromycin | 17 | $226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya | $347 | $48,02212 claims |
| Grifols USA, LLCGamunex-C | $53 | $25,80424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Dalton
- Andrew DoldDacula$1.1M
- Zandraetta Tims-CookAtlanta$848K
- Jeffrey StephensMacon$356K
- Jose VazquezAugusta$335K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Cheryl NewmanAugusta$128K
- Colleen KraftAtlanta$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.